- Home
- AMGN vs PFE Comparison
AMGN vs PFE Comparison
Compare AMGN & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- PFE
- Stock Information
- Founded
- AMGN 1980
- PFE 1849
- Country
- AMGN United States
- PFE United States
- Employees
- AMGN N/A
- PFE N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- PFE Biotechnology: Pharmaceutical Preparations
- Sector
- AMGN Health Care
- PFE Health Care
- Exchange
- AMGN Nasdaq
- PFE Nasdaq
- Market Cap
- AMGN 157.5B
- PFE 134.2B
- IPO Year
- AMGN N/A
- PFE N/A
- Fundamental
- Price
- AMGN $292.51
- PFE $24.59
- Analyst Decision
- AMGN Hold
- PFE Hold
- Analyst Count
- AMGN 20
- PFE 14
- Target Price
- AMGN $322.30
- PFE $29.92
- AVG Volume (30 Days)
- AMGN 2.7M
- PFE 38.5M
- Earning Date
- AMGN 08-05-2025
- PFE 08-05-2025
- Dividend Yield
- AMGN 3.25%
- PFE 6.99%
- EPS Growth
- AMGN 56.16
- PFE N/A
- EPS
- AMGN 10.94
- PFE 1.38
- Revenue
- AMGN $34,126,000,000.00
- PFE $62,464,000,000.00
- Revenue This Year
- AMGN $7.73
- PFE N/A
- Revenue Next Year
- AMGN $1.78
- PFE N/A
- P/E Ratio
- AMGN $26.78
- PFE $17.78
- Revenue Growth
- AMGN 15.56
- PFE 11.65
- 52 Week Low
- AMGN $253.30
- PFE $20.92
- 52 Week High
- AMGN $346.85
- PFE $31.54
- Technical
- Relative Strength Index (RSI)
- AMGN 52.53
- PFE 48.91
- Support Level
- AMGN $291.25
- PFE $25.14
- Resistance Level
- AMGN $302.38
- PFE $26.05
- Average True Range (ATR)
- AMGN 7.04
- PFE 0.47
- MACD
- AMGN 0.55
- PFE -0.02
- Stochastic Oscillator
- AMGN 66.26
- PFE 26.01
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.